

# Maria Josã© Pm Sã;

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7576036/publications.pdf>

Version: 2024-02-01

67  
papers

2,156  
citations

331538

21  
h-index

233338

45  
g-index

74  
all docs

74  
docs citations

74  
times ranked

3478  
citing authors

#	ARTICLE	IF	CITATIONS
1	Multiple Sclerosis Severity Score. <i>Neurology</i> , 2005, 64, 1144-1151.	1.5	836
2	Cognitive Dysfunction in Multiple Sclerosis. <i>Frontiers in Neurology</i> , 2012, 3, 74.	1.1	138
3	Psychological aspects of multiple sclerosis. <i>Clinical Neurology and Neurosurgery</i> , 2008, 110, 868-877.	0.6	116
4	Dendritic changes in the hippocampal formation of AIDS patients: a quantitative Golgi study. <i>Acta Neuropathologica</i> , 2004, 107, 97-110.	3.9	71
5	The effect of social support on the quality of life of patients with multiple sclerosis. <i>Arquivos De Neuro-Psiquiatria</i> , 2012, 70, 108-113.	0.3	65
6	Quality Assurance for Cerebrospinal Fluid Protein Analysis: International Consensus by an Internet-Based Group Discussion. <i>Clinical Chemistry and Laboratory Medicine</i> , 2003, 41, 331-7.	1.4	62
7	Exercise therapy and multiple sclerosis: a systematic review. <i>Journal of Neurology</i> , 2014, 261, 1651-1661.	1.8	58
8	International consensus on quality standards for brain health-focused care in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2019, 25, 1809-1818.	1.4	55
9	Selective loss of hilar neurons and impairment of initial learning in rats after repeated administration of electroconvulsive shock seizures. <i>Experimental Brain Research</i> , 2004, 154, 192-200.	0.7	50
10	Tau protein seems not to be a useful routine clinical marker of axonal damage in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2006, 12, 354-356.	1.4	47
11	Acute transverse myelitis: A practical reappraisal. <i>Autoimmunity Reviews</i> , 2009, 9, 128-131.	2.5	45
12	Novel TTC19 mutation in a family with severe psychiatric manifestations and complex III deficiency. <i>Neurogenetics</i> , 2013, 14, 153-160.	0.7	42
13	Classical immunomodulatory therapy in multiple sclerosis: how it acts, how it works. <i>Arquivos De Neuro-Psiquiatria</i> , 2011, 69, 536-543.	0.3	29
14	Social support network and quality of life in multiple sclerosis patients. <i>Arquivos De Neuro-Psiquiatria</i> , 2017, 75, 267-271.	0.3	29
15	Validation of the brief international cognitive assessment for multiple sclerosis (BICAMS) in the Portuguese population with multiple sclerosis. <i>BMC Neurology</i> , 2018, 18, 172.	0.8	28
16	Genotypes at the APOE and SCA2 loci do not predict the course of multiple sclerosis in patients of Portuguese origin. <i>Multiple Sclerosis Journal</i> , 2004, 10, 153-157.	1.4	27
17	Physiopathology of symptoms and signs in multiple sclerosis. <i>Arquivos De Neuro-Psiquiatria</i> , 2012, 70, 733-740.	0.3	27
18	Autonomic dysfunction in multiple sclerosis is better detected by heart rate variability and is not correlated with central autonomic network damage. <i>Journal of the Neurological Sciences</i> , 2016, 367, 133-137.	0.3	27

#	ARTICLE	IF	CITATIONS
19	AIDS does not alter the total number of neurons in the hippocampal formation but induces cell atrophy: a stereological study. <i>Acta Neuropathologica</i> , 2000, 99, 643-653.	3.9	26
20	Emerging Biosensing Technologies for Neuroinflammatory and Neurodegenerative Disease Diagnostics. <i>Frontiers in Molecular Neuroscience</i> , 2018, 11, 164.	1.4	25
21	Diagnostic Delay of Multiple Sclerosis in a Portuguese Population. <i>Acta Medica Portuguesa</i> , 2019, 32, 289-294.	0.2	22
22	Electrophoretic pattern of cerebrospinal fluid proteins in non-neoplastic infantile hydrocephalus. <i>Acta Neurologica Scandinavica</i> , 1978, 57, 317-328.	1.0	21
23	New insights into the burden and costs of multiple sclerosis in Europe: Results for Portugal. <i>Multiple Sclerosis Journal</i> , 2017, 23, 143-154.	1.4	20
24	Electrochemical Immunosensor for TNF $\alpha$ -Mediated Inflammatory Disease Screening. <i>ACS Chemical Neuroscience</i> , 2019, 10, 2676-2682.	1.7	19
25	Oligoclonal IgG bands in the cerebrospinal fluid of portuguese patients with multiple sclerosis: negative results indicate benign disease. <i>Arquivos De Neuro-Psiquiatria</i> , 2005, 63, 375-379.	0.3	19
26	Cognitive impairment and magnetic resonance imaging correlates in primary progressive multiple sclerosis. <i>Acta Neurologica Scandinavica</i> , 2017, 136, 109-115.	1.0	18
27	Prevalence of Autonomic Dysfunction in Patients with Multiple Sclerosis. <i>Acta Medica Portuguesa</i> , 2015, 28, 51-55.	0.2	15
28	A whole genome screen for association with multiple sclerosis in Portuguese patients. <i>Journal of Neuroimmunology</i> , 2003, 143, 112-115.	1.1	13
29	Month of birth and risk of multiple sclerosis in a Portuguese population. <i>Clinical Neurology and Neurosurgery</i> , 2013, 115, 1762-1765.	0.6	12
30	Depressive Symptomatology, Presenteeism Productivity, and Quality of Life. <i>Journal of Occupational and Environmental Medicine</i> , 2018, 60, 301-308.	0.9	12
31	Devic Disease With Abnormal Brain Magnetic Resonance Image Findings: The First Portuguese Case. <i>Archives of Neurology</i> , 2007, 64, 290.	4.9	10
32	Pain in Portuguese Patients with Multiple Sclerosis. <i>Frontiers in Neurology</i> , 2011, 2, 20.	1.1	10
33	The epidemiology of multiple sclerosis in the entre Douro e Vouga region of northern Portugal: a multisource population-based study. <i>BMC Neurology</i> , 2020, 20, 195.	0.8	10
34	Clinical and CSF cyto-proteic findings in 23 patients with CSF eosinophilia. <i>Acta Neurologica Scandinavica</i> , 1986, 73, 279-282.	1.0	9
35	Relapsingâ€“Remitting Multiple Sclerosis: Patterns of Response to Disease-Modifying Therapies and Associated Factors: A National Survey. <i>Neurology and Therapy</i> , 2014, 3, 89-99.	1.4	9
36	Multiple Sclerosis and Oligodendroglioma: An Exceptional Association. <i>Case Reports in Neurological Medicine</i> , 2014, 2014, 1-5.	0.3	9

#	ARTICLE	IF	CITATIONS
37	Gluten chorea. <i>Clinical Neurology and Neurosurgery</i> , 2015, 138, 8-9.	0.6	9
38	Pregnancy outcomes in Portuguese women with multiple sclerosis: The PREGNIMS study. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 28, 172-176.	0.9	9
39	Clinically isolated syndrome, oligoclonal bands and multiple sclerosis. <i>Clinical and Experimental Neuroimmunology</i> , 2020, 11, 33-39.	0.5	9
40	TyPed study: Natalizumab for the treatment of pediatric-onset multiple sclerosis in Portugal. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 51, 102865.	0.9	9
41	Dendritic right/left asymmetries in the neurons of the human hippocampal formation: a quantitative Golgi study. <i>Arquivos De Neuro-Psiquiatria</i> , 2007, 65, 1105-1113.	0.3	8
42	Social Characteristics and Quality of Life of Portuguese Multiple Sclerosis Patients. <i>Neurology and Therapy</i> , 2013, 2, 43-56.	1.4	8
43	Cerebrospinal fluid cytomorphologic findings in 41 intracranial tumors: a retrospective review. <i>Arquivos De Neuro-Psiquiatria</i> , 1995, 53, 218-226.	0.3	7
44	Etiopathogenesis, Classical Immunotherapy and Innovative Nanotherapeutics for Inflammatory Neurological Disorders. <i>Current Nanoscience</i> , 2011, 7, 2-20.	0.7	6
45	Neuromyelitis optica in Portugal (NEMIPORT) – A multicentre study. <i>Clinical Neurology and Neurosurgery</i> , 2015, 134, 79-84.	0.6	5
46	Multiple Sclerosis Treatment with Natalizumab: Analysis of a Hospital-Based Cohort. <i>Acta Medica Portuguesa</i> , 2014, 27, 437.	0.2	4
47	BRBN-T validation: adaptation of the Selective Reminding Test and Word List Generation. <i>Arquivos De Neuro-Psiquiatria</i> , 2015, 73, 867-872.	0.3	4
48	JC virus antibodies in Portuguese multiple sclerosis patients: JUSTIFY study results. <i>Journal of the Neurological Sciences</i> , 2019, 406, 116426.	0.3	4
49	Assessment of cognitive functions in patients with multiple sclerosis applying the normative values of the Rao’s brief repeatable battery in the Portuguese population. <i>BMC Neurology</i> , 2021, 21, 170.	0.8	4
50	Therapeutic inertia in relapsing-remitting multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 55, 103176.	0.9	4
51	State of the Art and Future Challenges in Multiple Sclerosis Research and Medical Management: An Insight into the 5th International Porto Congress of Multiple Sclerosis. <i>Neurology and Therapy</i> , 2020, 9, 281-300.	1.4	3
52	Infectious Risk Mitigation in Patients with Multiple Sclerosis under Disease-Modifying Therapies – the Experience of a Collaborative Neurology-Infectious Diseases Approach. <i>Journal of Central Nervous System Disease</i> , 2021, 13, 117957352110421.	0.7	3
53	Verbal Selective Reminding Test (six-trial administration): Regression-based norms for a portuguese version. <i>Applied Neuropsychology Adult</i> , 2018, 25, 523-531.	0.7	2
54	Trends in hospital readmissions in Multiple Sclerosis patients between 2009 and 2015. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 45, 102396.	0.9	2

#	ARTICLE	IF	CITATIONS
55	Natural history of relapsing remitting multiple sclerosis in a long-lasting cohort from a tertiary MS centre in Portugal. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 54, 103091.	0.9	2
56	Month of birth is not a definite risk factor for multiple sclerosis. <i>Arquivos De Neuro-Psiquiatria</i> , 2014, 72, 397-397.	0.3	2
57	Recognizing migraine in patients with multiple sclerosis improves the quality of health care. <i>Arquivos De Neuro-Psiquiatria</i> , 2019, 77, 599-600.	0.3	2
58	Pediatric neuromyelitis optica spectrum disorders in Portugal: A multicentre retrospective study. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 59, 103531.	0.9	2
59	Cytoproteic CSF findings in 33 MS patients: usefulness for diagnosis. <i>Acta Neurologica Scandinavica</i> , 1989, 79, 170-172.	1.0	1
60	Switching and Escalating Therapy in Long-Lasting Multiple Sclerosis: Not Always Necessary. <i>ISRN Neurology</i> , 2012, 2012, 1-5.	1.5	1
61	Paced Auditory Serial Addition Test (PASAT 3.0): Demographically corrected norms for the Portuguese population. <i>Applied Neuropsychology Adult</i> , 2018, 25, 417-423.	0.7	1
62	Pregnancy in multiple sclerosis: A reflection on the importance of individualizing management. <i>Clinical and Experimental Neuroimmunology</i> , 2021, 12, 171-174.	0.5	1
63	Defining the prodromal phase of multiple sclerosis based on healthcare access in a Portuguese Population - ProdMS Study. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 55, 103154.	0.9	1
64	Cerebral autoregulation is preserved in multiple sclerosis patients. <i>Journal of the Neurological Sciences</i> , 2017, 381, 298-304.	0.3	0
65	Recomendações e Consensos do Grupo de Estudos de Esclerose Múltipla e da Sociedade Portuguesa de Neurorradiologia sobre Ressonância Magnética na Esclerose Múltipla na Prática Clínica: Parte 1. <i>Acta Medica Portuguesa</i> , 2018, 31, 281.	0.2	0
66	RISCOP: Cognitive profile in a Portuguese cohort of radiological isolated syndrome patients: A case-control study. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 50, 102832.	0.9	0
67	Disease-modifying drugs for multiple sclerosis must be globally available according to therapeutic guidelines suitable to different regions of the world. <i>Arquivos De Neuro-Psiquiatria</i> , 2012, 70, 761-762.	0.3	0